GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme.

A live webcast of the presentation will be available on the investor section of the Anaptys website at A replay of the webcast will be available for at least 30 days following the event Anaptys is a ...

The EMA's acceptance of the prefilled syringe follows the European Commission’s (EC) approval of GSK's Jemperli, combined with chemotherapy for the treatment of advanced or recurrent endometrial ...

Harvey Jones isn't having much fun playing the GSK share price game. The FTSE 100 pharmaceutical stock must work hard to make ...

If the GSK (LSE: GSK) share price was a video game ... The success of new launches such as Jemperli in endometrial cancer and Apretude for HIV prevention suggests the drug pipeline is finally ...

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for the ...

Also in Europe, officials have endorsed GSK's Jemperli to treat all adult patients with primary advanced or recurrent endometrial cancer, including those with mismatch repair proficient (MMRp ...

GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031.